Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
HOME > Takeda’s £46 Billion Shire Buyout
Takeda’s £46 Billion Shire Buyout
-
Takeda Completes £46 Billion Shire Acquisition
January 8, 2019
-
After Thumbs-Up Given to Shire Buy, Weber’s Leadership Will Now Be Put to Test
December 12, 2018
-
Shareholders Give Blessing to £46 Billion Shire Pact as Weber Touts US Foothold
December 6, 2018
-
Takeda Shareholders OK £46 Billion Shire Takeover
December 5, 2018
-
Takeda Family Member Comes Forward for Final Appeal to Veto Shire Deal, but Admits Uphill Battle
December 4, 2018
-
Takeda Inks US$3.7 Billion Loan Accord with JBIC
December 4, 2018
-
Dissident Shareholder Group Hails Ex-Takeda Chief’s Opposition to Shire Deal
November 29, 2018
-
Dissident Takeda Shareholders Making Final Pitch to Thwart Shire Buyout
November 26, 2018
-
Takeda Gets European OK for Shire Deal with Strings Attached
November 21, 2018
-
Takeda to Issue US$5.5 Billion in Bonds for Shire Acquisition
November 21, 2018
-
Takeda to Procure €7.5 Billion in Bonds for Shire Acquisition
November 19, 2018
-
Big Takeda Could Debut as Early as January 8, De-facto Vote on Shire Deal Set for Dec. 5
November 13, 2018
-
Takeda Unveils Estimated Net Debt, Goodwill Post Shire Integration
November 2, 2018
-
Takeda Unveils Post-Acquisition Executive Team, 2 of 20 Members from Shire
November 1, 2018
-
Takeda Mulls Sale of Shire GI Pipeline to Clinch European Clearance
October 29, 2018
-
Takeda Earns Japan Clearance for Shire Acquisition
October 19, 2018
-
Takeda Alumni Shareholders Send Open Letter Questioning Shire Buyout
October 9, 2018
-
Takeda Gets China OK for Shire Takeover
September 18, 2018
-
Takeda Integration Team Prepping for Shire Takeover: Weber
August 1, 2018
-
Takeda Clinches Key US Clearance for Shire Takeover
July 10, 2018
ページ
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…